Aminosalicylic acid indications and usage: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Aminosalicylic acid}} {{CMG}} ; {{AE}}; {{chetan}} ==References== {{Reflist}} {{FDA}} Category:Antibiotics Category:Wikinfect")
 
mNo edit summary
 
(4 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Aminosalicylic acid}}
{{Aminosalicylic acid}}
{{CMG}} ; {{AE}}; {{chetan}}
{{CMG}}; {{AE}} {{chetan}}
 
 


==Indications and Usage==
PASER is indicated for the treatment of [[tuberculosis]] in combination with other active agents. It is most commonly used in patients with Multi-drug Resistant TB (MDR-TB) or in situations when therapy with isoniazid and rifampin is not possible due to a combination of resistance and/or intolerance. When PASER is added to the treatment regimen in patients proven or suspected drug resistance, it should be accompanied by at least one and preferably two other new agents to which the patient's organism is known or expected to be susceptible.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = PASER (AMINOSALICYLIC ACID) GRANULE, DELAYED RELEASE [JACOBUS PHARMACEUTICAL COMPANY, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f2753dc-5f0c-4f49-9335-e519afb69ba6 | publisher =  | date =  | accessdate =  }}</ref>


==References==
==References==

Latest revision as of 22:08, 25 December 2013

Aminosalicylic Acid
PASER® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Indications and Usage

PASER is indicated for the treatment of tuberculosis in combination with other active agents. It is most commonly used in patients with Multi-drug Resistant TB (MDR-TB) or in situations when therapy with isoniazid and rifampin is not possible due to a combination of resistance and/or intolerance. When PASER is added to the treatment regimen in patients proven or suspected drug resistance, it should be accompanied by at least one and preferably two other new agents to which the patient's organism is known or expected to be susceptible.[1]

References

  1. "PASER (AMINOSALICYLIC ACID) GRANULE, DELAYED RELEASE [JACOBUS PHARMACEUTICAL COMPANY, INC.]".

Adapted from the FDA Package Insert.